

Referances

- **Aberg ND, Brywe KG, Isgaard J (2006).** Aspects of growth hormone and insulin-like growth factor-I related to neuroprotection, regeneration, and functional plasticity in the adult brain. *Scientific-World Journal* ; 6 : 53 – 80.
- **Amato AA (2003)** . Sweet Success — A Treatment for McArdle's Disease *N.E.J.M.* ; 349; 2481-2482.
- **Amit T, Youdim MB and Hochberg Z (2000).** Clinical review 112: does serum growth hormone (GH) binding protein reflect human GH receptor function? *J. Clin. Endocrinol. Metab.* ; 85 : 927–932.
- **Andersen ST, Haller RG, Vissing J (2008).** Effect of oral sucrose shortly before exercise on work capacity in McArdle disease. *Arch Neurol* ; 65 : 786 –789.
- **Ansong AK, Li JS, Nozik-Grayck E, Ing R, Kravitz RM, Idriss SF, Kanter RJ, Rice H, Chen YT, Kishnani PS (2006).** Electrocardiographic response to enzyme replacement therapy for Pompe disease. *Genet Med* ; 8 : 297–301.
- **An Y, Young SP, Kishnani PS, Millington DS, Amalfitano A, Corzo D, Chen TT (2005).** Glucose tetrasaccharide as a biomarker for monitoring the therapeutic response to enzyme replacement therapy for Pompe disease, *Mol. Genet. Metab.*; 85 : 247–254.
- **Applegarth DA, Toone JR, Lowry RB (2000).** Incidence of inborn errors of metabolism in British Columbia, 1969-1996 . *J Pediatrics*; 105 : e10.
- **Bajpai A , and Menon PSN (2006).** Insulin like Growth Factors Axis and Growth Disorders. *Indian J Pediatr* ; 73 (1) : 67-71.
- **Baqué S, Joan J, Guinovart and Ferre JC (1997).** Glycogenin, the primer of glycogen synthesis, binds to actin . *FEBS Letters* ; 417(3) : 355-359.
- **Baumann G (2001).** Growth hormone binding protein 2001. *J. Pediatr. Endocrinol. Metab.*; 14 : 355–375.

- **Beauchamp NJ, Dalton A, Ramaswami U, Niinikoski H, Mention K , Kenny P, Raiman J, Walter J, Treacy E, Tanner S, Sharrard M (2007).** Glycogen storage disease type IX: High variability in clinical phenotype. *Molecular Genetics and Metabolism* ; 92: 88–99.
- **Beauloye V, Willems B, De Coninck V, Frank SJ, Edery M, Thissen JP (2002) .** Impairment of liver GH receptor signaling by fasting. *Endocrinology*; 143: 792–800.
- **Berryman DE , Christiansen JS, Johannsson G, Thorner MO , Kopchick JJ (2008).** Role of the GH/IGF-1 axis in lifespan and healthspan : Lessons from animal models. *Growth Hormone & IGF Research* ; 18 : 455–471.
- **Bhuiyan J, Al Odaib AN, Ozand PT (2003).** A simple, rapid test for the differential diagnosis of glycogen storage disease type III . *Clin Chim Acta.* ; 335 (1-2) : 21- 26.
- **Boguszewski CL (2003).** Molecular heterogeneity of human GH : from basic research to clinical implications. *J. Endocrinol. Invest.* ; 26 : 274–288.
- **Bohula EA, Salisbury AJ, Sohail M, Playford MP , Riedemann J , Southern EM, Macaulay VM (2003) .** The efficacy of small interfering RNAs targeted to the type 1 insulin-like growth factor receptor (IGF1R) is influenced by secondary structure in the IGF1R transcript. *J. Biol. Chem.* ; 278 : 15991–15997.
- **Bollen M, Keepens S, and Willy Stalmans W (1998).** Specific features of glycogen metabolism in the liver. *Biochemical Journal* ; 336 : 19-31.
- **Bozzola M, De Benedetti F, De Amici M, Jouret B, Travaglini P, Pagani S, Conte F, Tauber M (2003) .** Stimulating effect of growth hormone on cytokine release in children. *Eur. J. Endocrinol.* ; 149 : 397–401.
- **Brown-Borg HM (2009) .** Hormonal control of aging in rodents: The somatotrophic axis. *Molecular and Cellular Endocrinology* ;299 : 64–71.

- **Brown RJ, Adams JJ, Pelekanos RA, Wan Y, McKinstry WJ, Palethorpe K, Seeber RM, Monks TA, Eidne KA, Parker MW (2005).** Model for growth hormone receptor activation based on subunit rotation within a receptor dimer. *Nat Struct Mol Biol* ; 12 : 814–821.
- **Burren CP, Woods KA, Rose SJ, Tauber M, Price DA, Heinrich U, Gilli G, Razzaghy-Azar M , Al-Ashwal A , Crock PA , Rochiccioli P, Yordam N, Ranke MB (2001) .** Clinical and endocrine characteristics in atypical and classical growth hormone insensitivity syndrome. *Horm Res* ; 55 : 125-130.
- **Burwinkel B, Amat L, Gray RG, Matsuo N, Muroya K, Narisawa K, Sokol RJ, Vilaseca MA, Kilimann MW (1998b).** Variability of biochemical and clinical phenotype in X-linked liver glycogenosis with mutations in the phosphorylase kinase PHKA2 gene. *Hum Genet* ; 102 : 423-429.
- **Burwinkel B, Bakker HD, Herschkovitz E, Moses SW, Shin YS, Kilimann M.W (1998a).** Mutations in the liver glycogen phosphorylase gene (PYGL) underlying glycogenosis type VI. *Am J Hum Genet* ; 62 : 785-791.
- **Burwinkel B, Rootwelt T, Kvittingen EA (2003).** Severe phenotype of phosphorylase kinase-deficient liver glycogenosis with mutations in the PHKG2 gene. *Pediatr Res.* ; 54 (6) : 834 – 839.
- **Camacho-Hubner C, Woods KA , Clark AJL, Savage MO (2002).** Insulin-Like Growth Factor (IGF)-I Gene Deletion. *Reviews in Endocrine & Metabolic Disorders* ; 3 : 357 – 361.
- **Chen YT (2001).** The Metabolic and Molecular Bases of Inherited Disease. Vol. 1. New York , NY:. McGraw Hill : 1521-51.
- **Chou JY (2001).** The Molecular Basis of Type 1 Glycogen Storage Diseases *Current Molecular Medicine* ; 1: 25-44 .
- **Chou JY, Matern D, Mansfield BC, Chen YT (2002).** Type I Glycogen Storage Diseases: Disorders of the Glucose-6-Phosphatase Complex. *Current Molecular Medicine* ; 2: 121-143.

- **Cohen P, Rogol AD, Howard CP, Bright GM, Kappelgaard AM, Rosenfeld RG (2007).** Insulin growth factor-based dosing of growth hormone therapy in children : a randomized , controlled study . J. Clin. Endocrinol. Metab.; 92 : 2480–2486.
- **Colao A, di SC, Pivonello R, Cuocolo A, Spinelli L, Bonaduce D, Salvatore M, Lombardi G (2002).** The cardiovascular risk of adult GH deficiency (GHD) improved after GH replacement and worsened in untreated GHD : a 12-month prospective study. J Clin Endocrinol Metab ; 87 : 1088–1093.
- **Dai YJ, Chen L , Guo YP, Ren HT , Zhao YH, Wei M, Qiu ZO, Song HM (2009) .** Clinical and pathological features of glycogen storage disease type III . Zhonghua Yi Xue Ze Zhi ; 89 (15) : 1064 -1066.
- **De la Monte SM, Wands JR (2005).** Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system : relevance to Alzheimer's disease. J Alzheimers Dis ; 7 : 45–61.
- **Demo E, Frush D , Gottfried M , Koepke J, Boney A (2007).** Glycogen storage disease type III- hepatocellular carcinoma along-term complication?. J. Hepatol. ; 46 (3) : 492 - 498.
- **Drost MR, Schaart G , van Dijk P (2008).** Both type 1 and type 2a muscle fibers can respond to enzyme therapy in Pompe disease. Muscle Nerve; 37 : 251–255.
- **Dumana CH, Schlesinger L, Terwilliger R, Russell DS, Newton SS, Duman RS (2009).** Peripheral insulin-like growth factor-I produce antidepressant-like behavior and contributes to the effect of exercise. Behavioural Brain Research ; 198 : 366–371.
- **Dunger D B, Leonard JV and Preece M A (1984) .** Patterns of growth in the hepatic glycogenoses. Archives of Disease in Childhood; 59:657-660.

- **Ekstein J, Rubin BY, Anderson SL, Weinstein DA , Bach G , Abeliovich D, Webb M, Risch N (2004).** Mutation frequencies for glycogen storage disease Ia in the Ashkenazi Jewish population. *Am J Med Genet* ; 129 : 162-164 .

- **Fang P, Riedl S , Amselem S , Pratt KL, Little BM , Haeusler G , Hwa V, Frisch H , Rosenfeld RG (2007) .** Primary Growth Hormone (GH) Insensitivity and Insulin-Like Growth Factor Deficiency Caused by Novel Compound Heterozygous Mutations of the GH Receptor Gene : Genetic and Functional Studies of Simple and Compound Heterozygous States. *The Journal of Clinical Endocrinology & Metabolism* ; 92 (6) : 2223 - 2231.

- **Ferone D, Resmini E , Bocca L , Giusti M, Barreca A , Minuto F (2004) .** Current diagnostic guidelines for biochemical diagnosis of acromegaly. *Minerva Endocrinol.* ; 29 : 207–223.

- **Fisker S (2006).** Physiology and pathophysiology of growth hormone binding protein : Methodological and clinical aspects . *Growth Hormone & IGF Research* ; 16 : 1–28.

- **Fisker S , Hansen B , Fuglsang J , Kristensen K , Ovesen P, Orskov H , Jorgensen JO (2004).** Gene expression of the GH receptor in subcutaneous and intraabdominal fat in healthy females: relationship to GH-binding protein. *Eur. J. Endocrinol.*; 150 : 773–777.

- **Franceschi C , Olivieri F, Marchegiani F, Cardelli M , Cavallone L , Capri M., Salvioli S, Valensin S, De BG, Di IA, Caruso C, PaolissoG (2005).** Genes involved in immune response/inflammation, IGF1/insulin pathway and response to oxidative stress play a major role in the genetics of human longevity: the lesson of centenarians. *Mech Ageing Dev* ; 126 : 351– 361.

- **Franco LM, Krishnamurthy V, Bali D, Weinstein DA, Arn P, Clary B, Boney A, Sullivan J, Frush DP , Chen YT , Kishnani PS (2005) .** Hepatocellular carcinoma in glycogen storage disease type Ia: a case series. *J Inherit Metab Dis* ; 28 : 153-162 .

- **Friedrich N , Alte D, Volzke H, Spilcke-Liss E, Ludemann J, Lerch MM, Kohlmann T, Nauck M , Wallaschofski H (2008) .** Reference ranges of serum IGF-1 and IGFBP-3 levels in a general adult population : Results of the Study of Health in Pomerania (SHIP). *Growth Hormone & IGF Research* ; 18 : 228–237.
- **Fuglsang J and Ovesen P (2006).** Aspects of placental growth hormone physiology. *Growth Hormone & IGF Research* ;16 (2) : 67-85.
- **FukudaT, Ahearn M and Roberts A (2006)a.** Autophagy and mistargeting of therapeutic enzyme in skeletal muscle in Pompe disease, *Mol Ther.*; 14: 831–839 .
- **Fukuda T, Ewan L and Bauer M (2006)b.** Dysfunction of endocytic and autophagic pathways in a lysosomal storage disease. *Ann Neurol* ; 59 : 700–708.
- **Gardner, David G, Shoback, Dolores (2007).** Greenspan's Basic and Clinical Endocrinology 8th ed. pp. 193-201. New York: McGraw Medical. ISBN: 0071440119.
- **Ghigo E, Broglio F, Arvat E, Maccario M, Papotti M, Muccioli G (2005).** Ghrelin: more than a natural GH secretagogue and/or an orexigenic factor. *Clin. Endocrinol.* ; 62 : 1-17.
- **Goldberg T and Slonim AE (1993).** Nutrition therapy for hepatic glycogen storage diseases. *J Am Diet Assoc.*; 93 (12) : 1423-1430 .
- **Greenberg C C, Jurczak MJ , Danos AM, and Brady MJ (2006).** Glycogen branches out: new perspectives on the role of glycogen metabolism in the integration of metabolic pathways. *Am J Physiol Endocrinol Metab* ; 291 : 1-8.
- **Grehl T, Muller K , Vorgerd M , Tegenthoff M , Malin JP, Zange J (1998).** *Neuromuscul. Disord.*; 8 (7) : 480-488.
- **Grzelkowska-Kowalczyk K. and Wieteska W (2005) .** The impairment of IGF-I-stimulated protein synthesis and activation of protein kinase B, p70(S6k), MAP kinase, and p90(rsk) in mouse C2C12 myogenic cells exposed to high glucose and high insulin . *Pol. J. Vet. Sci.* ; 8 : 241–250.
- **Haller RG, Wyrick MA, Taivassalo T, Vissing J (2006).** Aerobic conditioning :an effective therapy in McArdle’s disease. *Ann Neurol* ; 59 : 922–928.

- **Hawes ML, Kennedy W, O'Callaghan MW, Thurberg BL (2007).** Differential muscular glycogen clearance after enzyme replacement therapy in a mouse model of Pompe disease. *Mol Genet Metab* ; 91 : 343–351.
- **Helen RM, Peter CH, David RM, James VL and Philip JL (2003).** The regulation of growth in glycogen storage disease type 1. *Clinical Endocrinology* ; 58 : 332–339.
- **Hesselink RP, Schaart G, Wagenmakers AJ, Drost MR, van der Vusse GJ (2005).** Age-related morphological changes in skeletal muscle cells of acid alpha-glucosidase knockout mice. *Muscle Nerve*; 33: 505–513.
- **Hidaka F, Sawada H , Matsuyama M, Nuno H (2005).** A novel mutation of the PHKA2 gene in a patient with X-linked liver glycogenosis type 1. *Pediatr Int* ; 47: 687- 690.
- **Hirschhorn R and Reuser AJJ (2001).** Glycogen Storage Disease Type II (GSDII). In: Scriver CR, Beaudet AL, Sly WS and Valle D, Editors, *The Metabolic and Molecular Bases of Inherited Disease* (8th edn.), McGraw-Hill, pp: 3389–3420.
- **Hua G.H., Chen S.L., Yu J.N., Cai K.L., Wu C.J., Li Q.L., Zhang C.Y., Liang A.X., Han L., Geng L.Y., Shen Z., Xu D.Q., Yang L.G. ,(2009) .** Polymorphism of the growth hormone gene and its association with growth traits in Boer goat bucks. *Meat Science* ; 81 : 391–395.
- **Ingle SA, Moulick ND, Ranadive NU , Khedekar K (2004).** Hepatocellular failure in glycogen storage disorder type III . *J. Assoc Physician India.*; 52 : 158-60.
- **Jeay S , Sonenshein GE, Postel-Vinay MC., Kelly PA, Baixeras E (2002).** Growth hormone can act as a cytokine controlling survival and proliferation of immune cells: new insights into signaling pathways. *Mol Cell Endocrinol* ; 188 : 1-7 .
- **Ji HF, Wang WL, Shen Y, Zhang M, LiangTB, Wu J, Xu X, Yan S and Zheng SS (2009).** Reduced-size liver transplantation for glycogen storage disease . *Hepatobiliary Pancreat Dis Int* ; 8 (1) : 21- 25 .

- **Jürim J and JürimT (2006).** Influence of Insulin-Like Growth Factor–1 and Leptin on Bone Mineral Content in Healthy Premenopausal Women. *Experimental Biology and Medicine* ; 231 : 1673-1677.
- **Kalkan Ucar S, Coker M , So“zmen E, Goksen Simsek D, Darcan SA (2009).** monocentric pilot study of an antioxidative defense and hsCRP in pediatric patients withglycogen storage disease type IA and III . *Nutrition, Metabolism & Cardiovascular Diseases* ;19, 383-390.
- **Kallwass H , Carr C, Gerrein J, Titlow M, Pomponio R, Bali D, Dai J, Kishnani P, Skrinar A, Corzo D, Keutzer J (2007).** Rapid diagnosis of late-onset Pompe disease by fluorometric assay of alpha-glucosidase activities in dried blood spots. *Mol Genet Metab.* ; 90 : 449–452.
- **Kim AH, Khursigara G, Sun X, Franke TF, Chao MV (2001).** Akt phosphorylates and negatively regulates apoptosis signal-regulating kinase 1. *Mol Cell Biol* ; 21(3) : 893 - 901.
- **Kim YJ, Yoon JH, Kim CY, Kim LH , Park BL , Shin HD (2006).** IGF2 polymorphisms are associated with hepatitis B virus clearance and hepatocellular carcinoma. *Biochem Biophys Res Commun* ; 346 : 38–44.
- **Kishnani PS, Steiner RD and Bali D (2006)a .** Pompe disease diagnosis and management guideline. *Genet Med* ; 8 : 267–288 .
- **Kishnani PS, Steiner RD, Bali D, Berger K, Byrne BJ, Case LE, Crowley JF, Downs S, Howell RR, Kravitz RM, Mackey J, Marsden D, Martins A.M (2006)b.** Pompe disease diagnosis and management guideline. *Genet Med.* ; 8 : 267–288.
- **Klinger B, Laron Z (1994).** Renal function in Laron syndrome patients treated by insulin-like growth factor-I . *Pediatr Nephrol* ; 8 : 684–688.
- **Kornreich L , Horev G , Schwarz M , Karmazyn B, Laron Z (2002).**Laron syndrome abnormalities: spinal stenosis, os odontoideum, degenerative changes of the atlanto-odontoid joint, and small oropharynx. *AJNR Am J Neuroradiol* ; 23: 625–631.

- **Koshy AB, Ramaswamy KA , Correa MA , Rekha SW (2006).**Glycogen storage disease : report of 17 cases from southern India . Indian Journal of Gastroenterology ; 25 : 180-182.
- **Kravitz RM , Mackey J, DeArmey S, Kishnani PS (2005).** Pulmonary function findings in patients with infantile Pompe disease. Proc Am Thorac Soc ; 2 : A 186 .
- **Kursunluoglu R, Turgut S, Akin F, Bastemir M, Kaptanoglu B, Genc O, Turgut G (2009).** Insulin-like Growth Factor-I Gene and Insulin-like Growth Factor Binding Protein-3 Polymorphism in Patients with Thyroid Dysfunction. Archives of Medical Research ; 40 : 42-47.
- **Laron Z (2004).** Laron Syndrome (Primary Growth Hormone Resistance or Insensitivity) : The Personal Experience 1958–2003 .The Journal of Clinical Endocrinology & Metabolism ; 89 (3) : 1031-1044.
- **Laughlin GA, Barrett-Connor E, Criqui MH, Kritz-Silverstein D (2004) .** The prospective association of serum insulin-like growth factor I (IGF-I) and IGF-binding protein-1 levels with all cause and cardiovascular disease mortality in older adults : the Rancho Bernardo Study . The J. Clin. Endocrinol. Metab. ; 89 : 114–120.
- **Laura A, Pérez-Casellas, Xiaoying Wang , Kristy D, Howard, Mark W, Rehage, Donna D, Strong , Thomas A (2009).** Linkhart. Nuclear Factor I transcription factors regulate IGF binding protein 5 gene transcription in human osteoblasts. Biochimica et Biophysica Acta (BBA), Gene Regulatory Mechanisms ; 1789 (2) : 78-87.
- **Lee J and Menon RK (2005).** Molecular Defects in the Growth Hormone-IGF Axis . Indian J Pediatr ; 72 (2) : 145 - 148.
- **Lee P, Mather S and Owens C (1994).** Hepatic ultrasound findings in the glycogen storage diseases. Br J Radiol. ; 67 (803) : 1062 - 1066.

- **Le Roith D (2003)** . The Insulin-Like Growth Factor System. *Experimental Diab. Res.*; 4 : 205–212.
- **Le Roith D, Bondy C, Yakar S, Liu J , Butler A (2001)**. The Somatomedin Hypothesis: 2001. *Endocrine Reviews* ; 22 (1) : 53-74.
- **Lindsey A, Norbeck, JeVrey D, Kittilson, Mark A, Sheridan (2007)**. Resolving the growth-promoting and metabolic effects of growth hormone: Differential regulation of GH–IGF-I system components. *General and Comparative Endocrinology* ; 151 : 332–341.
- **Lossos A, Barash V, Soffer D, Argov Z, Gomori M, Ben-Nariah Z, Abramsky O, Steiner I (1991)**. Hereditary branching enzyme dysfunction in adult polyglucosan body disease: a possible metabolic cause in two patients. *Ann Neurol* ; 30 : 655- 662.
- **Lucchiari S, Pagliarani S, Salani S, Filocamo M, Di Rocco M., Melis D, Rodolico C, Musumeci O, Toscano A, Bresolin N, Comi GP (2006)**. Hepatic and neuromuscular forms of glycogenosis type III: nine mutations in AGL. *Hum Mutat* ; 27 : 600 - 601
- **Maughan R (2005)**. Basic metabolism II : carbohydrate. *Surgery (Oxford)* ; 23 (5) : 154-158.
- **Melendez R , Melendez-Hevia E, and Canela EI (1999)**. The fractal structure of glycogen : A clever solution to optimize cell metabolism. *Biophys J* ; 77: 1327–1332.
- **Melis D, Parenti G, Della Casa R, Sibilio M, Romano A, Di Salle F, Elefante R, Mansi G, Santoro L, Perretti A, Paludetto R, Sequino L (2004)** . Brain damage in glycogen storage disease type I . *J Pediatr* ; 144 : 637-642.
- **Mellies U, Stehling F, Dohna-Schwake C, Ragette R, Teschler H, Voit T (2005)**. Respiratory failure in Pompe disease : treatment with noninvasive ventilation. *Neurology* ; 64 : 1465– 1467.

- **McCusker RH, Strle K , Broussard SR , Dantzer R , Bluthé' RM , Kelley KW (2006)** . Crosstalk between insulin-like growth factors and proinflammatory cytokines , in : Ader R., Dantzer R., Glaser R., Heijnen C., Irwin M., Padgett D., Sheridan J. (Eds.), Psychoneuroimmunology, vol. 1, Academic Press, New York, pp. 171–191.

- **Molitch ME, Clemmons DR, Malozowski S , Merriam GR , Shalet SM , Vance ML (2006)**. "Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society Clinical Practice Guideline". J. Clin. Endocrinol. Metab. ; 91 (5) : 1621–34.

- **Momose S , Kunimoto S , Osono M , Ikeda D (2009)**. Inhibitors of insulin-like growth factor-1 receptor tyrosine kinase are preferentially cytotoxic to nutrient-deprived pancreatic cancer cells. Biochemical and Biophysical Research Communications ; 380 : 171–176.

- **Moreland RJ , Jin X , Zhang XK , Decker RW, Albee KL (2005)**. Lysosomal acid alpha-glucosidase consists of four different peptides processed from a single chain precursor. J Biol Chem ; 280 : 6780–6791.

- **Moses SW, and Parvari R (2002)**. The Variable Presentations of Glycogen Storage Disease Type IV: A Review of Clinical, Enzymatic and Molecular Studies. Current Molecular Medicine ; 2: 177-188.

- **Muller D, Santer R, Krawinkel M, Christiansen B, Schaub J (1997)**. Fanconi-Bickel syndrome presenting in neonatal screening for galactosaemia. J Inherit Metab Dis ; 20 : 607-608.

- **Nakajima H, Raben N, Hamaguchi T, Yamasaki T (2002)**. Phosphofructokinase Deficiency ; Past , Present and Future . Current Molecular Medicine ; 2: 197-212.

- **Naomi H (2001)**. Diencephalohypophysial disease. Hypopituitarism, GH hyposecretory short stature disease, and pituitary adenoma. J. Clinical Endocrinology ; 49: 35-45.

- **National Committee for Clinical and Laboratory Standards (1999).** Procedures for handling and processing of blood samples ; second edition; approved guideline. NCCLS Document H18- A2; Wayne(PA) ; NCCLS oct.40.
- **Nedic O, Nikolic JA, Malenkovic V, Baricevic- Jones I (2007).** Insulin-like growth factors (IGFs) and their binding proteins (IGFBPs) as biomarkers of catabolism. JMB ; 26 : 17–24 .
- **Nelson DL , and Cox MM (2004).** Ch. 15 of Principles of Biochemistry, "Principles of Metabolic Regulation, Illustrated with Glucose and Glycogen Metabolism" - 4 edition ; New York : W. H Freeman and Company.
- **Nindl BC, Hymer WC, Deaver DR, Kraemer WJ (2001).** "Growth hormone pulsatility profile characteristics following acute heavy resistance exercise". J. Appl. Physiol.; 91 (1 : 163–72.
- **Nindl BC, Pierce JR, Durkot MJ, Tuckow AP , Kennett MJ, Nieves JW , Cosman F, Alemany JA, Hymer WC (2008) .** Relationship between growth hormone in vivo bioactivity, the insulin-like growth factor-I system and bone mineral density in young, physically fit men and women. Growth Hormone & IGF Research ; 18 : 439–445.
- **Norrelund H (2005).** The metabolic role of growth hormone in humans with particular reference to fasting. Growth Hormone & IGF Research ; 15 : 95–122.
- **O'Connor JC, Robert H McCusker , Strle K, Johnson RW, antzer R, Kelley KW (2008) .** Regulation of IGF-I function by proinflammatory cytokines : At the interface of immunology and endocrinology. Cellular Immunology ; 252 : 91–110.
- **Özen H (2007).** Glycogen storage diseases: New perspectives. World J Gastroenterol ;13 (18) : 2541-2553.
- **Palacios N, Sanchez-Franco F, Fernandez M, Cacicedo L (2005).** Intracellular events mediating insulin-like growth factor I induced oligodendrocyte development: modulation by cyclic AMP. J Neurochem ; 95(4) : 1091 - 1097.

- **Pell JM, Salih DAM, Cobb LJ, Tripathi G , Drozd J (2005).** The Role of Insulin-Like Growth Factor Binding Proteins in Development . Reviews in Endocrine & Metabolic Disorders ; 6 : 189–198.
- **Pérez M, Ruiz JR, Fernandez del Valle M, Andreu AL, Arenas J, Lucia A (2009).** The second wind phenomenon in very young McArdle's patients. Neuromuscular Disorders ; 19 : 403–405.
- **Phillips (2005).** Growth disorders: hereditary. Encyclopedia of life sciences. Wiley , New York , pp 1–6.
- **Quinlivan R, Beynon RJ and Martinuzzi A (2008).** Pharmacological and nutritional treatment for McArdle disease (glycogen storage disease type V). Cochrane Database Syst ; 2 : CD003458.
- **Tang NL, Hui J, Young E , Worthington V, To KF, Cheung KL, Li CK, Fok TF (2003).** A novel mutation (G233D) in the glycogen phosphorylase gene in a patient with hepatic glycogen storage disease and residual enzyme activity. Mol Genet Metab ; 79 : 142-145 .
- **Rake JP, Visser G, Labrune P, Leonard JV, Ullrich K, Smit GP (2002) a.** Glycogen storage disease type I: diagnosis, management, clinical course and outcome. Results of the European Study on Glycogen Storage Disease Type I (ESGSD I). Eur J Pediatr ; 161 : 20–34.
- **Rake JP, Visser G, Labrune P, Leonard JV, Ullrich K, Smit GP (2002) b.** Guidelines for management of glycogen storage disease type I - European Study on Glycogen Storage Disease Type I (ESGSD I). Eur J Pediatr ; 161 : 112–119.
- **Ranke MB (2005).** Insulin-like growth factor-I treatment of growth disorders, diabetes mellitus and insulin resistance. Trends Endocrinol Metab ; 16 : 190–197.
- **Renahan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M (2004).** Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet ; 363 :1346–1353.

- **Rodriguez S, Gaunt TR, and Day INM (2007).** Molecular genetics of human growth hormone, insulin-like growth factors and their pathways in common disease. *Hum Genet* ; 122 : 1–21.
- **Rosen CJ and Pollak M (1999)** . Circulating IGF-I: New Perspectives for a New Century . *Trends in Endocrinology and Metabolism* ; 10(4) : 136 - 141.
- **Saltik-Temizel IN, Coskun T, Yuce A, Kocak N (2005).** Fanconi-Bickel syndrome in three Turkish patients with different homozygous mutations. *Turk J Pediatr* ; 47: 167-169.
- **Santer R, Kinner M, Steuerwald U, Kjargaard S, Skovby F, Simonsen H, Shaiu WL, Chen YT, Schneppenheim R, Schaub J (2001).** Molecular genetic basis and prevalence of glycogen storage disease type IIIA in the Faroe Islands . *Eur J Hum Genet* ; 9 : 388-391.
- **Santer R, Schneppenheim R, Dombrowski A, Gotze H, Steinmann B, Schaub J (1997).** Mutations in GLUT2, the gene for the liver-type glucose transporter, in patients with Fanconi-Bickel syndrome. *Nat Genet* ; 17: 324-326 .
- **Savage MO, Attie KM, David A, Metherell LA, Clark AJ, Camacho-Hubner C (2006).** Endocrine assessment , molecular characterization and treatment of growth hormone insensitivity disorders. *Nat Clin Pract Endocrinol Metab* ; 2 : 395–407.
- **Savage MO, Burren CP, Blair JA, Woods KA, Metherell L, Clark AJ, Camacho-Hubner C (2001).** Growth hormone insensitivity : pathophysiology, diagnosis, clinical variation and future perspectives. *Horm .Res.* ;55 (Suppl) : 32–35.
- **Savage MO, Camacho-Hubner C, Dunger DB (2004).** Therapeutic applications of the insulin-like growth factors. *Growth Horm IGF Res* ; 14 : 301–308.
- **Scarth JP (2006).** "Modulation of the growth hormone-insulin-like growth factor (GH-IGF) axis by pharmaceutical, nutraceutical and environmental xenobiotics: an emerging role for xenobiotic-metabolizing enzymes and the transcription factors regulating their expression. A review". *Xenobiotica* ; 36 (2-3) : 119–218.

- **Scheepens A, Modersheim TA, Gluckman PD (2005)** .The role of growth hormone in neural development. *Horm Res* ; 64 (Suppl 3) : 66–72.
- **Schippers HM , Smit GPA , Rake JP and Visser G (2003).** Characteristic growth pattern in male X-linked phosphorylase-b kinase deficiency. *J. Inherit. Metab.Dis.*;26:3-47.
- **Schoser B, Hil V and Raben N (2008).** Therapeutic Approaches in Glycogen Storage Disease Type II/Pompe Disease. *Neurotherapeutics* ; 5 (4) : 569-578.
- **Sherlock M and Toogood AA (2007)** . Aging and the growth hormone/insulin like growth factor-I axis. *Pituitary* ; 10 : 189–203.
- **Sivakumar K, Vasconcelos O, Goldfarb L, Dalakas MC.(1996).** Glycogen storage disease type VII . *Neurology* ; 46 (5) : 1337-1342.
- **Slonim AE, Bulone L and Minikes J (2006).** Benign course of glycogen storage disease type IIb in two brothers: nature or nurture?. *Muscle Nerve* ; 33 : 571–574.
- **Smaniotto S, de Mello-Coelho V, Villa-Verde DM, Pléau JM, Postel-Vinay MC, Dardenne M, Savino W (2005)** . Growth hormone modulates thymocyte development in vivo through a combined action of laminin and CXC chemokine ligand 12.. *Endocrinology* ; 146 : 3005–3017.
- **Smith RG, Sun Y, Betancourt L, Asnicar M (2004).** Growth hormone secretagogues: prospects and potential pitfalls. *Best Pract Res Clin Endocrinol Metab* ; 18 (3) :333–347.
- **Soler Palacín P, Tomasa Wörner N, Sánchez de Toledo Sancho J, Yeste Fernández D, Gussinyé Canadell M, Carrascosa Lezcano A (2004).** Glycogen storage disease type IX presenting as abdominal distention, hepatomegaly and hypoglycemia during infancy. *An Pediatr (Barc)* ;61 (5) : 438-441.
- **Stollberger C, Finsterer J and Bittner R E (1997)** . Diagnostic approaches in glycogen storage disease type VII . *Lancet* ; 349 (9061): 1292.

- **Stryer L (1995).** Biochemistry - fourth edition; New York : W. H. Freeman and Company.
- **Stylianopoulos C L (2005).** regulation of carbohydrate metabolism. Eyclopedia of Human Nutrition ; 23: 309-315.
- **Van den Eijnden MJ and Strous GJ(2007).** Autocrine Growth Hormone: Effects on Growth Hormone Receptor Trafficking and Signaling. Molecular Endocrinology; 21: 2832–2846.
- **Van den Hout HM, Hop W, van Diggelen OP, Smeitink JA, Smit GP, Poll-The BT, Bakker HD, Loonen M.C, de Klerk JB, Reuser AJ, van der Ploeg AT (2003).**The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature. Pediatrics.; 112 : 332–340.
- **van der Lely AJ, Tschöp M, Heiman ML, Ghigo E (2004).** Biological, physiological, pathophysiological and pharmacological aspects of ghrelin. Endocr. Rev. ; 25 : 426–457.
- **Van der Ploeg AT and Reuser A JJ (2008).** Pompe's disease. The LANCET; 372 :1342 - 1353.
- **Venkatasubramanian G , Chittiprol S , Neelakantachar N (2007).** Insulin and insulin-like growth factor-1 abnormalities in antipsychotic-naïve schizophrenia. Am J Psychiatry ; 164 : 1557–1560.
- **Very NM and Sheridan MA (2002).** The role of somatostatins in the regulation of growth in fish. Fish Physiol. Biochem.; 27 : 217-226.
- **Visser G , Rake JP, Labrune P, Leonard JV , Moses S , Ullrich K , Wendel U, Smit GP (2002)c .** Consensus guidelines for management of glycogen storage disease type 1b - European Study on Glycogen Storage Disease Type 1.
- **Vissing J, and Haller R.G (2003).** The Effect of Oral Sucrose on Exercise Tolerance in Patients with McArdle's Disease. N.E.J.M. ; 349 : 2503-2509.
- **Vorgerd M (2008).** Therapeutic Options in Other Metabolic Myopathies. NeuroTherapeutics ; 5 : 579–582.

- **Walenkamp MJE, Karperien M, Pereira AM, Hilhorst-Hofstee Y, van Doorn J, Chen JW, Mohan S, Denley A, Forbes B, van Duyvenvoorde HA, van Thiel SW, Sluimers CA, Bax JJ (2005).** Homozygous and heterozygous expression of a novel IGF-I mutation. *J Clin Endocrinol Metab* ; 90 : 2855 - 2864.
- **Waters MJ, Hoang HN, Fairlie DP, Pelekanos RA, Brown RJ (2006).** New insights into growth hormone action. *J Mol Endocrinol* ; 36 : 1–7.
- **Weinstein DA, Correia CE, Saunders AC, Wolfsdorf JI (2006).** Hepatic glycogen synthase deficiency: an infrequently recognized cause of ketotic hypoglycemia. *Mol Genet Metab* ; 87: 284-288.
- **Weinstein DA, Somers MJ and Wolfsdorf JI (2001).** Decreased urinary citrate excretion in type 1a glycogen storage disease. *J Pediatr* ; 138 : 378–82.
- **Weinstein DA and Wolfsdorf JI (2002).** Effect of continuous glucose therapy with uncooked cornstarch on the long-term clinical course of type 1a glycogen storage disease. *Eur J Pediatr* ; 161: 35– 39.
- **Weinstein DA and Wolfsdorf JI (2004).** Glycogen Storage Disease. *Encyclopedia of Gastroenterology* ; 12 : 232- 237.
- **Willems PJ, Gerver WJ, Berger R, Fernandes J (1990).** The natural history of liver glycogenosis due to phosphorylase kinase deficiency: a longitudinal study of 41 patients. *Eur J Pediatr* ; 149 : 268-271.
- **Winchester B, Bali D, Bodamer OA, Caillaud C, Christensen E, Cooper A, Cupler E (2008).** Methods for a prompt and reliable laboratory diagnosis of Pompe disease Report from an international consensus meeting. *Molecular Genetic and Metabolism* ; 93 (3): 275-281.
- **Winkel LP, Hagemans ML, van Doorn PA (2005).** The natural course of non-classic Pompe's disease; a review of 225 published cases. *J Neurol* ; 252 : 875–884.

- **Winkel LP, Hagemans ML , Van Doorn PA , Loonen MC, Hop WJ, Reuser AJ , van der Ploeg AT (2005).** Clinical manifestation and natural course of late-onset Pompe's disease in 54 Dutch patients. *Brain* ; 128 : 671–677.
- **Wolfsdorf JI and Weinstein DA (2003).** Glycogen storage diseases. *Rev. Endocr. Metab. Disord.*; 4 : 95–102.
- **Yakar S, Le roith D, and Brodt P (2005) .** The role of the growth hormone / insulin-like growth factor axis in tumor growth and progression: lessons from animal models. *Cytokine Growth Factor Rev.* ; 16 : 407–420.
- **Yang J, Anzo M, Cohen P (2005).** Control of aging and longevity by IGF-I signaling. *Exp Gerontol* ; 40 : 867–872.
- **Yao S, Qi XK, Xiong B, ZhangW, Zheng RL, Yuan Y (2009).** The clinical and pathological characteristics of a patient with glycogen storage disease IV. *Zhonghua Nei Ke Za Zhi* ; 48 (5) : 380-382.
- **Yoshikawa M , Fukui K , Kuriyama S, Tsujimoto T, Nakatani Y, Toyokawa Y, Kurematsu Y, Awata J, Shiroy A, Fukui H, Tsutsumi M (2001).** Hepatic adenomas treated with percutaneous ethanol injection in a patient with glycogen storage disease type Ia. *J Gastroenterol.* ; 36 : 52–61.
- **Zheng WH and Quirion R (2006).** Insulin-like growth factor-1 (IGF-1) induces the activation / phosphorylation of Akt kinase and cAMP response element-binding protein (CREB) by activating different signaling pathways in PC12 cells. *BMC Neuroscience* ; 7 : 51.
- **Zhuang TF, Qiu ZQ, Wei M, Huang SZ(2005).** Mutation analysis of glycogen debrancher enzyme gene in five Chinese patients with glycogen storage disease type III . *Zhonghua Er Ke Za Zhi* ; 43 (2) : 85-88.
- **Zimakas PJ and Rodd CJ (2005).** Glycogen storage disease type III in Inuit children. *CMAJ.* ; 172 (3) : 355 - 358.

